Nektar Therapeutics (NKTR) EBITDA (2010 - 2026)

Nektar Therapeutics' EBITDA history runs 17 years deep, the most recent figure standing at -$39.1 million for Q1 2026.

• In Q1 2026, EBITDA rose 23.28% year-over-year to -$39.1 million; the TTM figure through Mar 2026 stood at -$34.4 million (up 72.1% YoY), while the FY2025 annual figure was -$34.5 million, up 67.22% from the prior year.
• EBITDA was -$39.1 million for Q1 2026 at Nektar Therapeutics, down from $78.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $78.0 million in Q4 2025 to a low of -$160.7 million in Q2 2022.
• Historically, EBITDA has averaged -$48.3 million across 5 years, with a median of -$44.9 million in 2023.
• The sharpest annual moves came in 2023 and 2025: EBITDA slumped 46.38% in 2023, then soared 443.3% in 2025.
• A 5-year view of EBITDA shows it stood at -$52.5 million in 2022, then jumped by 36.13% to -$33.5 million in 2023, then surged by 142.82% to $14.3 million in 2024, then jumped by 443.3% to $78.0 million in 2025, then tumbled by 150.1% to -$39.1 million in 2026.
• The last three EBITDA figures came in at -$39.1 million (Q1 2026), $78.0 million (Q4 2025), and -$31.7 million (Q3 2025), per Business Quant data.